Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

General Anxiety Disorder Anxiety Disorders Generalized Anxiety Disorder Mental Disorders

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Pivotal Research Center, Mesa, Arizona, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Not available at time of registration

Treatment and study plan

GABITRIL (tiagabine hydrochloride; CEP-6671)

Drug

Sponsors and collaborators

Lead sponsor

Cephalon

Industry

Registry information

Official study title

A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder

Important dates

Study start: 2003
Primary completion: 2005
First posted: Oct 6, 2005
Registry last updated: Apr 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed